Biotech Investors & VC Firms in Barcelona
14 firms in this list, with a median first check of $215K. 4 of them lead rounds. Generated from verified public data and updated continuously.
Ysios Capital
BarcelonaSeries A–Late Stage$5.4M – $21.6M
25 people
Nina Capital
BarcelonaPre-Seed–Series A$215K – $1.6M
18 people
Invivo Capital Partners
BarcelonaPre-Seed–Series A$2.2M – $4.3M
11 people
Capital Cell
BarcelonaPre-Seed–Growth
Criteria Bio Ventures
BarcelonaSeed–Late Stage
7 people
WA4STEAM
BarcelonaPre-Seed–Series A
6 people
Masia
BarcelonaPre-Seed–Seed$135K – $270K
Grow Venture Partners
BarcelonaPre-Seed–Series A$108K – $216K
8 people
Improve Ventures
BarcelonaPre-Seed–Series A$100K – $1M
5 people
Ship2B Ventures
BarcelonaSeed–Series A$216K – $2.2M
Emesa Corporación Empresarial
Barcelona
Aliath Bioventures
BarcelonaSeed–Series A
5 people
Healthequity
BarcelonaSeed–Late Stage
1 person
Columbus Venture Partners
ValenciaSeed
1 person
Frequently asked questions
- Who are the top biotech investors & vc firms in barcelona?
- Top biotech investors & vc firms in barcelona include Ysios Capital, Nina Capital, Invivo Capital Partners, Capital Cell, Criteria Bio Ventures, WA4STEAM, Masia, Grow Venture Partners — 14 firms in total meet the criteria.
- What is the typical first check among biotech investors & vc firms in barcelona?
- The median first check among the 14 biotech investors & vc firms in barcelona tracked here is $215K.
- How many biotech investors & vc firms in barcelona lead rounds?
- 4 of the 14 biotech investors & vc firms in barcelona tracked here lead investment rounds.
Related lists
Investors & VC Firms in North America (14143)Investors & VC Firms in United States (13281)Investors & VC Firms in Europe (5575)Crypto & Web3 Investors & VC Firms (4830)Investors & VC Firms in Global (4158)SaaS Investors & VC Firms (3865)AI & Machine Learning Investors & VC Firms (3769)Fintech Investors & VC Firms (3726)Investors & VC Firms in Asia-Pacific (3574)Healthtech Investors & VC Firms (3415)
Data sourced from public filings and firms' own websites — see our methodology.




































